Switch to:
More From Other Websites
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data... Jul 22 2015
​Short sellers retreat from Sarepta and OvaScience Jul 20 2015
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs Jul 20 2015
​Sarepta makes plans to start late-stage tests of two more Duchenne drugs Jul 17 2015
Sarepta Soars on FDA Submission for Duchenne Drug Jul 16 2015
Sarepta Therapeutics One Step Closer to Drug Approval Jul 03 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece Jul 01 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Sarepta Hires ex-Genzyme Head Henri Termeer as Adviser Jul 01 2015
Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company Jul 01 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... Jun 30 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30 2015
Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog Jun 30 2015
BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog Jun 30 2015
5 Biotech Stocks On Deck With The FDA Jun 30 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK